EMILY PARKER: Open Payments
NPI 1639404288 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$374 in 17 payments from 12 companies in 2025. Trend: 2023 $358 · 2024 $423 · 2025 $374
Food & beverage: $374
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Geron Corporation | 2 | $57 |
| Novartis Pharmaceuticals Corporation | 2 | $48 |
| KYOWA KIRIN, INC. | 2 | $32 |
| Genentech USA, Inc. | 1 | $30 |
| Janssen Biotech, Inc. | 1 | $22 |
| SpringWorks Therapeutics, Inc. | 1 | $20 |
| GENZYME CORPORATION | 1 | $19 |
| Gilead Sciences, Inc. | 1 | $19 |
| PharmaEssentia USA Corporation | 1 | $18 |
Products named: FRUZAQLA, RYTELO, SCEMBLIX, POTELIGEO, Itovebi, DARZALEX, OGSIVEO, SARCLISA.
Industry payments across MI — which companies pay providers there.
